Literature DB >> 34737071

Socio-medical studies of individuals self-treating with helminths provide insight into clinical trial design for assessing helminth therapy.

Aarushi Venkatakrishnan1, Joshua T Sarafian1, Kateřina Jirků-Pomajbíková2, William Parker3.   

Abstract

The virtually complete loss of intestinal worms, known as helminths, from Western society has resulted in elimination of a range of helminth-induced morbidities. Unfortunately, that loss has also led to inflammation-associated deficiencies in immune function, ultimately contributing to widespread pandemics of allergies, autoimmunity, and neuropsychiatric disorders. Several socio-medical studies have examined the effects of intentional reworming, or self-treatment with helminths, on a variety of inflammation-related disorders. In this study, the latest results from ongoing socio-medical studies are described. The results point toward two important factors that appear to be overlooked in some if not most clinical trials. Specifically, (a) the method of preparation of the helminth can have a profound effect on its therapeutic efficacy, and (b) variation between individuals in the effective therapeutic dosage apparently covers a 10-fold range, regardless of the helminth used. These results highlight current limits in our understanding of the biology of both hosts and helminths, and suggest that information from self-treatment may be critical for clinical evaluation of the benefits and limits of helminth therapy.
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical trials; Dose escalation; Helminth; Inflammation; Self-treatment

Mesh:

Year:  2021        PMID: 34737071     DOI: 10.1016/j.parint.2021.102488

Source DB:  PubMed          Journal:  Parasitol Int        ISSN: 1383-5769            Impact factor:   2.230


  2 in total

Review 1.  Between a hygiene rock and a hygienic hard place: Avoiding SARS-CoV-2 while needing environmental exposures for immunity.

Authors:  William Parker; Joshua T Sarafian; Sherryl A Broverman; Jon D Laman
Journal:  Evol Med Public Health       Date:  2021-02-12

2.  Authors' response to Graham Rook's commentary.

Authors:  William Parker; Joshua T Sarafian; Sherryl A Broverman; Jon D Laman
Journal:  Evol Med Public Health       Date:  2021-04-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.